Evidence map›Paper›PMID 39066263›Full record

ArticleViruses2024

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease.

Dylan M Johnson, Terry Juelich, Lihong Zhang, Jennifer K Smith, Birte K Kalveram, David Perez, Jeanon Smith, Michael R Grimes, Tania Garron, Maricela Torres and 5 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dylan M JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0000-0002-3630-0588
Terry JuelichDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0000-0001-7034-2602
Lihong ZhangDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Jennifer K SmithDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Birte K KalveramDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
David PerezOffice of Biosafety, Texas A&M University, College Station, TX 77843, USA.
Jeanon SmithOffice of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0009-0008-1047-5153
Michael R GrimesCenter for Molecular and Translational Human Infectious Diseases Research, Houston Methodist, Houston, TX 77030, USA.
Tania GarronDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Maricela TorresDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Shane MasseyOffice of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Trevor BraselDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
David W C BeasleyDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Alex N FreibergDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.ORCID 0000-0001-8413-8960
Jason E ComerDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

Funding

NIAID NIH HHS HHSN272201700040Ithe National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services HHSN272201700040I/ HHSN27200007
6 · The paper itself

Abstract

Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013-2016 West African EVD outbreak of favipiravir treatment. However, mixed results from these studies hindered regulatory approval of favipiravir for the indication of EVD. This study examined the influence of route of administration, duration of treatment, and treatment schedule of favipiravir in immune competent mouse and guinea pig models using rodent-adapted

Indexed as

AmidesAntiviral AgentsDisease Models, AnimalEbolavirusHemorrhagic Fever, EbolaMice, Inbred BALB CPyrazinesAnimalsDrug Administration RoutesDrug Administration ScheduleFemaleGuinea PigsMiceAmidesAntiviral AgentsfavipiravirPyrazinesanimal modelEbola virusEBOVfavipiravirfilovirusT-705

Identifiers

PMID39066263
PMCPMC11281331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.